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Radiation dosimetry of new radiopharmaceuticals generally starts with studies in small animals such as mice and rats. The traditional technique has long been ex vivo measurement 
of the biodistribution over time using harvested organs at different times post administration of the radiopharmaceutical. Since this approach requires a significant amount of 
animals, dynamic microPET studies, where the complete biodistribution of the tracer over time can be determined in vivo in a single scan, are an invaluable alternative. Due to known 
imaging artifacts and limitations, such as partial volume effect, a hybrid technique combining harvesting organs (post-scan) and dynamic imaging was introduced to achieve a cross-
calibration to account for these limitations. 
Scaling errors in the PET TACs are likely caused by quantification errors such as partial volume effects and image artifacts, which caused an underestimation in activities measured by 
microPET imaging only in brain, heart and lung (mean: 30%, 10% and 28%, respectively) and an overestimation in kidney and liver (mean: 21% and 30%). The use of the hybrid 
imaging technique to cross-calibrate the TACs improved the accuracy of the imaging-based dosimetry estimates. Therefore the hybrid technique combining dynamic imaging and 
harvesting organs (post-scan) is a suitable alternative to the gold standard ex vivo radioassay method using harvested organs at different time points. It yields comparable results yet 
reduces significantly the amount of animals needed in the study and can accelerate data acquisition.  
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Materials & Methods 
The tissue distribution over time of 6-[18F]Fluoro-L-DOPA was determined by: 
  
1) Radioassay of harvested organs in isoflurane-anaesthetized mice: 
• Brain, heart, kidneys, liver, lung, spleen and testes 
• At 2, 5, 10, 30, 60, 120 minutes post injection, n=4 at each time point 
• Average bodyweight 23.5 ± 1.75 g; Average injected activity 8.47 ± 1.45 MBq 
2) Dynamic PET imaging acquired using a FOCUS 120 microPET over 120 minutes after 
injection of 6-[18F]Fluoro-L-DOPA followed by radioassay of harvested organs in 
isoflourane-anesthetized mice (n=4). CT images were obtained using a GE eXplore 120 
micro-CT prior to dynamic PET imaging:  
• Time frames: 6x5s, 6x10s, 3x20s, 5x30s, 5x60s, 8x150s, 6x300s, 6x600s. 
• Average bodyweight 22.1 ± 1.21 g; Average injected activity 7.66 ± 1.62 MBq 
Clearly identifiable organs were manually segmented in the reconstructed co-
registered PET/CT images and organ time-activity-curves (TACs) were obtained. TACs 
from PET were multiplied with the cross-calibration factor between PET activity and 
Gamma counter activity levels. 
TACs from both methods were extrapolated from a simulated 35 g standard mouse to 
a 70 kg standard male human using a technique based on organ to bodyweight ratios 
[Kirschner et al., 1975]:  
 
 
A bladder voiding scenario was used to simulate excretion every 2 h. The absorbed 
doses in major human organs were calculated using the extrapolated TACs with the 










































Figure 4 – Average residence times (left) and average total body with major organ doses (right, correlation 
calculated for all dose values, not just major organs) 
Figure 1 – Brain uptake and 3D representation of co-registered micro PET/CT image (left: sagittal plane through brain and skull, middle: coronal plane through 
brain and skull,  right: 3D segmentation) 
Figure 2 – Human average TACs derived with hybrid technique (left) and derived from tissue distribution (right)  
Figure 3 – Bland-Altman plots of Liver TACs (left, highest correlation) and Lung TACs (right, lowest correlation) 
r = 0.99 
p < 0.001 
r = 0.85 
p < 0.001 




























































































• TACs were derived using the tissue distribution and the hybrid technique, average 









• Differences at high activity levels were revealed in Bland-Altman plots for TACs 



















• The highest doses were received by organs in excretion pathways comprising 
bladder (0.142 mGy/MBq both methods), kidneys and liver (see Figure 4) 
• The effective total body dose was 0.0193 mSv/MBq for hybrid and 0.0189 
mSv/MBq for pure harvesting based method 
 
 
